1. Pediatric Patent Extensions
Ben Peck
Legislative Representative
Public Citizen’s Congress Watch

2. Revenue to Industry; Costs for Consumers
$29.6 billion in additional sales over 20 years to brand name drug industry
$592 million per year in additional profits for the brand name drug industry
$14 billion additional drug costs for consumers over 20 year period
Source: U.S. Food and Drug Administration, “The Pediatric Exclusivity Provision: Status Report to
Congress,” January 2001.

3. Additional Revenues vs. Cost of Testing (In Millions)
Source: Sales data for year 2000 comes from Public Citizen calculated added revenues and added costs to consumers based on a formula used by the U.S. Food and Drug Administration in a January 2001 report to Congress.

4. Drug industry influence
Senate Sponsors of Pediatric Patent Extension Legislation, Chistopher Dodd (D-Conn.) and Mike DeWine (R-Ohio) rank 3rd and 7th in total contributions from the industry since Dodd has received $165,698 and DeWine has received $132,800.
Members of the House subcommittee who voted against reining in giveaway to brand name industry receive more than twice as much in campaign contributions from the industry as those who voted for reining in the giveaway, $65,000 vs. $25,000 on average since 1990.
Source: Public Citizen analysis of data from the Center for Responsive Politics.

5. Children’s Groups in a Box
“This is an incentive that has become such a windfall for blockbuster drugs,” said Paul Glaser. “However, as I see it, that is all part and parcel of buying into our system that stresses money and power and where there is very little room for mandating a moral imperative. There is no choice.”
Paul Glaser, chairman of the Elizabeth Glaser Pediatric AIDS Foundation (Testimony before the Senate Health Education Labor and Pensions Committee, May 8, 2001)